Enterprise Value
-81.5M
Cash
189.5M
Avg Qtr Burn
-7.219M
Short % of Float
4.36%
Insider Ownership
15.99%
Institutional Own.
85.33%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JTX-4014 (Pimivalimab) (PD-1 inhibitor) Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Vopratelimab (IgG1 agonist) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
JTX-8064 (LILRB2/ILT4 Inhibitor) Details Solid tumor/s | Phase 1/2 Update |